Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

NCT07701161

RecruitingN/A

Sponsor: Neurogen Biomarking LLC

Conditions: Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers

Countries: United States

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Eligibility overview

Sex: ALL

Age: 40 Years to 90 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed

Exclusion Criteria:

* Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Locations (5)
  • Chicago, Illinois, United States
  • Dearborn, Michigan, United States
  • Flint, Michigan, United States
  • Owosso, Michigan, United States
  • Winston-Salem, North Carolina, United States